← Back to Clinical Trials
Recruiting NCT05257135

NCT05257135 A Clinico-biological Database in Cachexia in Patients With Colon Cancer

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05257135
Status Recruiting
Phase
Sponsor Institut du Cancer de Montpellier - Val d'Aurelle
Condition Colon Cancer
Study Type INTERVENTIONAL
Enrollment 150 participants
Start Date 2021-12-23
Primary Completion 2026-05

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Biological collection

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 150 participants in total. It began in 2021-12-23 with a primary completion date of 2026-05.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Creation of a prospective clinico-biological database dedicated to cachexia and undernutrition in order to carry out future research projects, to improve our knowledge of colon cancer and cachexia and to optimize the therapeutic management of patients

Eligibility Criteria

Inclusion Criteria: 1. Age ≥ 18 years old, 2. Patient treated at the Montpellier Regional Cancer Institute for colon cancer not eligible for surgery (of the primary tumor or associated metastases), whether undergoing treatment or not, 3. Patient requiring treatment for colon cancer (chemotherapy, targeted therapy, etc.), 4. Patient having accepted the constraints of the research and the blood samples planned for the research 5. Patient affiliated to Social Protection system 6. Informed consent form signed Exclusion Criteria: 1. Patient requiring surgery (for treatment of colon cancer or metastasis) 2. Patient with exclusive peritoneal carcinomatosis 3. Patient requiring radiotherapy 4. Patient unable to understand or comply with study instructions or requirements for psychological, family, social or geographical reasons 5. Pregnant and/ or breastfeeding women 6. Patient cared for an emergency context

Contact & Investigator

Central Contact

Jean-Pierre Bleuse, MD

✉ DRCI-icm105@icm.unicancer.fr

📞 4 67 61 31 02

Principal Investigator

Pierre Senesse, MD

STUDY CHAIR

Institut régional du cancer de Montpellier

Frequently Asked Questions

Who can join the NCT05257135 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Colon Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05257135 currently recruiting?

Yes, NCT05257135 is actively recruiting participants. Contact the research team at DRCI-icm105@icm.unicancer.fr for enrollment information.

Where is the NCT05257135 trial being conducted?

This trial is being conducted at Montpellier, France.

Who is sponsoring the NCT05257135 clinical trial?

NCT05257135 is sponsored by Institut du Cancer de Montpellier - Val d'Aurelle. The principal investigator is Pierre Senesse, MD at Institut régional du cancer de Montpellier. The trial plans to enroll 150 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology